Health Condition 1: L562- Photocontact dermatitis [berloquedermatitis]
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with Clinical diagnosis of chronic actinic dermatitis including: Actinic Prurigo Actinic cheilitis Lichenoid photodermatitis Photoallergic dermatitis Phytophotodermatitis Actinic reticuloid 2. Age group more than 18 years of age. 3. The patient should have given written consent before the investigations and starting the drug. 4. The patient should be able and willing and fit, in the view of the investigator, to comply with all study procedures
Exclusion criteria
Exclusion criteria: A .Patients with acute photodermatitis. B. Patients allergic to tofacitinib or azathioprine. C. Patient with cardiac diseases or hematological diseases (including angina, coronary artery disease, recent or acute myocardial infarction, pericardial effusion,anemia,coagulation disorders) D. Patients with cerebrovascular diseases E.Patients with deranged liver and kidney function. F. Patients with recent infections. G. Patient with positive mantoux test. H.Patients with a recent or past history of tuberculosis I.Patient with a positive Interferon Gamma Release Assay (IGRA) test. J.Patients with a history of acute phototoxic diseases. K.Phototoxic rash related to some drug. L.Patients with Low Thiopurine Methyl Transferase(TPMT) value ( O.Patients having diabetes mellitus. P.Patients with any immunocompromised conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the efficacy and safety of oral tofacitinib with azathioprine in chronic actinic dermatitisTimepoint: At baseline,15 days,30 days,2 months and 3 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not applicableTimepoint: Not applicable | — |
Countries
India
Contacts
Krishna Vishwa Vidyapeeth